Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAZINGA: Zanubrutinib in Anti-MAG Antibody Neuropathy
2025-523091-23-00Phase 2Authorised
- Sponsor
- Azienda Ospedaliero-Universitaria di Padova
- Start
- Dec 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zanubrutinib in peripheral neuropathy, Waldenström macroglobulinemia (WM), marginal zone B-cell lymphoma (MZL) and 2 more, sponsored by Azienda Ospedaliero-Universitaria di Padova. Planned start Dec 2025; status: authorised.
02
Drugs
zanubrutinib
03
Conditions
peripheral neuropathyWaldenström macroglobulinemia (WM)marginal zone B-cell lymphoma (MZL)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)monoclonal gammopathy of undetermined significance (MGUS)
Beyond the preview
Go deeper on 2025-523091-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523091-23-00.